Caitlin Raymond: Understanding Risks in Rare Group A Subtypes with Anti-A1 Antibodies in Transfusion Medicine
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at the University of Wisconsin-Madison, shared a post on LinkedIn:
”In transfusion medicine, some risks feel larger than they actually are — not because they’re common, but because the evidence we have is skewed toward worst-case scenarios.
I recently wrote a follow-up blog post on rare group A subtypes with anti-A1 antibodies, prompted by a real case and a conversation with a reference laboratory.
Case reports tell us what can go wrong. Reference labs see what actually does go wrong — and how often.
This post walks through:
- When cold reacting anti-A1 actually becomes dangerous
- Why malignancy-associated cases don’t generalize
- When to choose group O blood for rare group A subtypes
If you’ve ever felt uneasy making decisions where the literature offers warnings but no denominator, this one’s for you.”

Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers